Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
167.29 USD
-0.3%
Market Closed
Updated:
Apr 26, 2024
Abbvie Inc
Cash from Investing Activities
|
Abbvie Inc
Cash from Investing Activities Peer Comparison
Comparables:
GILD
AMGN
MRNA
VRTX
REGN
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash from Investing Activities
$4.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Abbvie Inc's Cash from Investing Activities?
Cash from Investing Activities
-2B
USD
-2B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Cash from Investing Activities amounts to -2B USD.
What is Abbvie Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-15%
-15%
Over the last year, the Cash from Investing Activities growth was -222%. The average annual Cash from Investing Activities growth rates for Abbvie Inc have been 62% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
